News
-
-
COMMUNIQUÉ DE PRESSE
EQS-Adhoc: Pentixapharm Holding AG: FDA grants “Study May Proceed” for Phase 3 Study; Intended Capital Increase with Subscription Rights of up to 10 Million Shares; BaFin Financial Reporting Enforcement Review
Pentixapharm Holding AG receives FDA clearance for Phase 3 study, plans capital increase of up to 10 million shares with subscription rights, and faces BaFin financial review -
-
-
COMMUNIQUÉ DE PRESSE
Pentixapharm Announces IND Submission to FDA for Phase 3 PANDA Study of First-in-Class CXCR4-Targeted Cardiovascular Diagnostic
Pentixapharm submits IND to FDA for Phase 3 PANDA study of CXCR4-targeted cardiovascular diagnostic, aiming at precision diagnostics in primary aldosteronism -
-
-
-
-
